NGeneBio Co., Ltd. (KOSDAQ: 354200)
South Korea
· Delayed Price · Currency is KRW 3,175.00
-225.00 (-6.62%)
Oct 11, 2024, 9:00 AM KST
NGeneBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 4,989 | 4,351 | 11,018 | 7,163 |
| Other Revenue | 0 | 0 | - | - |
| Revenue | 4,989 | 4,351 | 11,018 | 7,163 |
| Revenue Growth (YoY) | -16.14% | -60.51% | 53.81% | - |
| Cost of Revenue | 3,015 | 4,505 | 6,889 | 4,773 |
| Gross Profit | 1,974 | -153.65 | 4,128 | 2,390 |
| Selling, General & Admin | 10,540 | 7,834 | 7,389 | 6,011 |
| Research & Development | 3,723 | 4,505 | 4,584 | 4,456 |
| Other Operating Expenses | 217.54 | 58.85 | 69.25 | 148.6 |
| Operating Expenses | 15,524 | 13,271 | 12,728 | 11,122 |
| Operating Income | -13,551 | -13,425 | -8,599 | -8,732 |
| Interest Expense | -1,768 | -1,781 | -665.44 | -155.25 |
| Interest & Investment Income | 607.23 | 991.59 | 852.58 | 261.76 |
| Earnings From Equity Investments | - | - | - | 199.05 |
| Currency Exchange Gain (Loss) | 53.07 | 23.95 | 84.28 | 0.71 |
| Other Non Operating Income (Expenses) | 240.52 | 1,659 | -1,332 | 28.42 |
| EBT Excluding Unusual Items | -14,418 | -12,531 | -9,660 | -8,397 |
| Gain (Loss) on Sale of Investments | -508.1 | -526.16 | -144.52 | 1.77 |
| Gain (Loss) on Sale of Assets | 0.56 | -20.85 | -0.99 | -11.15 |
| Asset Writedown | -94.28 | -97.62 | -34.1 | -24.56 |
| Pretax Income | -14,144 | -13,175 | -9,839 | -8,431 |
| Income Tax Expense | -315.69 | -315.69 | - | - |
| Earnings From Continuing Operations | -13,829 | -12,860 | -9,839 | -8,431 |
| Minority Interest in Earnings | 544.53 | 90.92 | 53.96 | - |
| Net Income | -13,284 | -12,769 | -9,785 | -8,431 |
| Net Income to Common | -13,284 | -12,769 | -9,785 | -8,431 |
| Shares Outstanding (Basic) | 13 | 13 | 12 | 12 |
| Shares Outstanding (Diluted) | 13 | 13 | 12 | 12 |
| Shares Change (YoY) | 2.29% | 1.66% | 0.89% | - |
| EPS (Basic) | -1035.05 | -1006.63 | -784.21 | -681.70 |
| EPS (Diluted) | -1035.69 | -1007.00 | -784.21 | -682.00 |
| Free Cash Flow | -11,637 | -9,553 | -8,849 | -10,546 |
| Free Cash Flow Per Share | -906.70 | -753.13 | -709.15 | -852.68 |
| Gross Margin | 39.56% | -3.53% | 37.47% | 33.36% |
| Operating Margin | -271.64% | -308.56% | -78.05% | -121.90% |
| Profit Margin | -266.29% | -293.48% | -88.82% | -117.70% |
| Free Cash Flow Margin | -233.27% | -219.57% | -80.32% | -147.22% |
| EBITDA | -11,795 | -12,081 | -7,325 | -7,702 |
| EBITDA Margin | -236.44% | -277.67% | -66.49% | -107.52% |
| D&A For EBITDA | 1,756 | 1,344 | 1,274 | 1,030 |
| EBIT | -13,551 | -13,425 | -8,599 | -8,732 |
| EBIT Margin | -271.64% | - | -78.05% | -121.90% |
| Advertising Expenses | - | 348.42 | 336.73 | 287.33 |
Source: S&P Capital IQ. Standard template. Financial Sources.